Possible Spironolactone Induced Intracranial Hypertension in a Patient with Androgenetic Alopecia: A Case Report

Hamad Albraidi1, , Omar Alzuman1, , Abdulmajeed Alajlan2, *
1 College of Medicine, King Saud University, Riyadh, Saudi Arabia
2 Department of Dermatology, King Saud University, Riyadh, Saudi Arabia

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 3060
Abstract HTML Views: 2002
PDF Downloads: 1180
ePub Downloads: 1202
Total Views/Downloads: 7444
Unique Statistics:

Full-Text HTML Views: 1504
Abstract HTML Views: 729
PDF Downloads: 457
ePub Downloads: 319
Total Views/Downloads: 3009

© 2018 Albraidi et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: ( This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Dermatology, King Saud University, PO Box 7805, Riaydh 11472, Saudi Arabia, Tel: +966114691426; E-mail:

† Both authors contributed equally to this work


Spironolactone is a well-known drug with many indications. In dermatology, it may be used for treating androgenetic alopecia with a high androgen level. A patient with idiopathic papilledema that was inactive for many years experienced a significant increase in intracranial pressure after receiving spironolactone. The symptoms were resolved soon after the medication was discontinued. This report draws physicians’ attention to such rare adverse events that may have unwanted consequences.

Keywords: Spironolactone, Idiopathic Intracranial Hypertension, Papilledema, Androgenetic Alopecia, Drug, Androgen.